Company news

Jiangsu Hengrui Pharmaceuticals Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Announcement on Progress in A-share Repurchase

June 2, 2026

Announcement on Convening the Q1 2026 Performance Briefing

May 27, 2026

Announcement on Implementation of Dividend Distribution for 2025

May 20, 2026

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

May 12, 2026

Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic Cardiomyopathy

May 11, 2026

Announcement on Resolutions of the 3rd Meeting of the 10th Board of Directors

April 29, 2026

Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth

April 22, 2026

Announcement on Inclusion of Drug in Breakthrough Therapy Designation List

April 20, 2026

Announcement on Resolutions of the 1st Meeting of the 10th Board of Directors

April 16, 2026

Announcement on Completion of Unlocking the Lockup Period of Employee Stock Ownership Plan

April 3, 2026

Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy

March 30, 2026

Announcement on Convening the 2025 Annual Performance and Cash Dividend Briefing

March 27, 2026

Hengrui Pharma Announces Strong 2025 Annual Results

March 25, 2026

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization

March 16, 2026

Announcement on Election of Employee Representative Directors for the 10th Board of Directors

March 2, 2026

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization and Inclusion into the Priority Review Program

February 24, 2026

Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide

February 10, 2026

Announcement on FDA Acceptance for Review of the Resubmitted Biologics License Application for Camrelizumab for Injection

February 2, 2026

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma

January 30, 2026

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

December 31, 2025

Announcement on Resolutions of the 15th Meeting of the 9th Board of Supervisors

December 28, 2025

Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

November 4, 2025

Hengrui Pharma Reports Steady Growth in Q3 2025 Driven by Innovation and Global Expansion

October 27, 2025

Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025

October 21, 2025

Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power

October 20, 2025

Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)

September 24, 2025

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

September 7, 2025

Hengrui Pharma and Braveheart Bio Enter Exclusive License Agreement for Cardiac Myosin Inhibitor HRS-1893

September 5, 2025

Jiangsu Hengrui Pharmaceuticals: Hengrui Pharma Has Announced its Record-breaking First-half 2025 Results

August 20, 2025

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results

July 29, 2025

Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

July 27, 2025

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

July 22, 2025

Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

July 15, 2025

Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD

July 8, 2025

Jiangsu Hengrui Pharmaceuticals: Hengrui Pharma Announces Positive Data of Two ADC Programs at the AACR Annual Meeting 2023

April 10, 2023

← Newer news releases

Decks

The 5 newest of 9 decks. Every deck is listed under its year.